Please assess the completion status of the following clinical trial:

Trial Title: Nitisinone (NTBC) In Different Age Groups Of Patients With Alkaptonuria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of alkaptonuria with documented increased excretion of homogentisic acid~2. Willing and able to provide written, signed informed consent, or age appropriate written assent and written informed consent by a legally authorized representative after the study has been explained, prior to any research-related procedures.~3. Willing and able to be seen in the UCSD Clinical Center for Research or a satellite site for the study visits~4. Possession of insurance coverage for standard of care procedures, clearly stated in the consent forms~Exclusion Criteria:~1. Baseline tyrosine level above 250 mmol/mL~2. Baseline serum creatinine, creatine kinase, or transaminases 2x upper limit of normal~3. Baseline anemia or thrombocytopenia~4. Current participation in another investigational medication trial.~5. Pregnant or lactating women~6. Current keratopathy, contact use or uncontrolled glaucoma~7. History myocardial infarction or arrhythmia~8. History of pulmonary insufficiency~9. Psychiatric illness that may interfere with compliance or communication~10. Current malignancy or hypertension

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitisinone (Type: EXPERIMENTAL): all subjects will receive open-label nitisinone

Based on this trial design, predict the completion outcome and termination type (if applicable).